After this study they have to run the combined study. Sounds like NasRAT planned for delays this time. He said he wasn't filing till the end of the year.
Is this criteria for this bioequivalence trial in a form that can be read and digested for the investor that understands the data? Probably not, because elite never publishes anything for peer review. They just release a pr saying that "top of the line results are on the way."
News 
Market Data 
Discover 
AI
